Table 4 Type of antipsychotic and thymoregulator prescribed by age in all Pays de la Loire areas (n = 3 658 000) from July 1, 2013 to June 30, 2014
From: Influence of socioeconomic status on antipsychotic prescriptions among youth in France
Age | Total n = 2706 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
0–4 y n = 44 | 5–9 y n = 441 | 10–14 y n = 1140 | 15–17 y n = 1081 | |||||||
Antipsychotic type and combination | n | % | n | % | n | % | n | % | n | % |
SGAP single prescription | 6 | 13.6 | 133 | 30.2 | 392 | 34.4 | 369 | 34.1 | 900 | 33.3 |
FGAP single prescription | 36 | 81.8 | 237 | 53.7 | 447 | 39.2 | 390 | 36.1 | 1110 | 41.0 |
FGAP (only usedTourette) | - | - | 5 | 1.1 | 3 | 0.3 | 3 | 0.3 | 11 | 0.4 |
Valproate or Valpromide | - | - | 3 | 0.7 | 8 | 0.7 | 19 | 1.7 | 30 | 1.1 |
SGAP + FGAP | 2 | 4.5 | 62 | 14.1 | 262 | 23.0 | 252 | 23.3 | 578 | 21.5 |
SGAP+ Valproate or Valpromide | - | - | 1 | 0.2 | 8 | 0.7 | 8 | 0.8 | 17 | 0.6 |
FGAP+ Valproate or Valpromide | - | - | - | - | 2 | 0.2 | 8 | 0.8 | 10 | 0.3 |
Various combination | - | - | - | - | 18 | 1.2 | 32 | 3.0 | 50 | 1.8 |
FGAP/SGAP ratio | 86.3/18.1 | 68.9/44.5 | 63.2/58.6 | 60.3/58.2 | 65.1/57.1 | |||||